{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:50:48Z","timestamp":1792691448340,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 031L0137B"],"award-info":[{"award-number":["FKZ 031L0137B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 031L0137B"],"award-info":[{"award-number":["FKZ 031L0137B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 031L0137B"],"award-info":[{"award-number":["FKZ 031L0137B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 031L0137B"],"award-info":[{"award-number":["FKZ 031L0137B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 031L0137B"],"award-info":[{"award-number":["FKZ 031L0137B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 031L0137B"],"award-info":[{"award-number":["FKZ 031L0137B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 031L0137B"],"award-info":[{"award-number":["FKZ 031L0137B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 031L0137B"],"award-info":[{"award-number":["FKZ 031L0137B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 031L0137B"],"award-info":[{"award-number":["FKZ 031L0137B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 031L0137B"],"award-info":[{"award-number":["FKZ 031L0137B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 031L0137B"],"award-info":[{"award-number":["FKZ 031L0137B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 031L0137B"],"award-info":[{"award-number":["FKZ 031L0137B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 031L0137B"],"award-info":[{"award-number":["FKZ 031L0137B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson\u2019s Research","doi-asserted-by":"publisher","award":["14761"],"award-info":[{"award-number":["14761"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Inflammation modifies the incidence and progression of Parkinson\u2019s disease (PD). By using 30 inflammatory markers in CSF in 498 people with PD and 67 people with dementia with Lewy bodies (DLB) we show that: (1) levels of ICAM-1, Interleukin-8, MCP-1, MIP-1 beta, SCF and VEGF were associated with clinical scores and neurodegenerative CSF biomarkers (A\u03b21-42, t-Tau, p181-Tau, NFL and \u03b1-synuclein). (2) PD patients with GBA mutations show similar levels of inflammatory markers compared to PD patients without GBA mutations, even when stratified by mutation severity. (3) PD patients who longitudinally developed cognitive impairment during the study had higher levels of TNF-alpha at baseline compared to patients without the development of cognitive impairment. (4) Higher levels of VEGF and MIP-1 beta were associated with a longer duration until the development of cognitive impairment. We conclude that the majority of inflammatory markers is limited in robustly predicting longitudinal trajectories of developing cognitive impairment.<\/jats:p>","DOI":"10.1038\/s41531-023-00476-2","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T07:03:04Z","timestamp":1678518184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD"],"prefix":"10.1038","volume":"9","author":[{"given":"Stefanie","family":"Lerche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Roeben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Wurster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca Laura","family":"Fries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Deuschle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Waniek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingolf","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Jakobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3042-8174","authenticated-orcid":false,"given":"Thomas O.","family":"Joos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Knorpp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6785-181X","authenticated-orcid":false,"given":"Nicole","family":"Schneiderhan-Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7515-8596","authenticated-orcid":false,"given":"Kathrin","family":"Brockmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"476_CR1","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/ng.3043","volume":"46","author":"MA Nalls","year":"2014","unstructured":"Nalls, M. A. et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson\u2019s disease. Nat. Genet 46, 989\u2013993 (2014).","journal-title":"Nat. Genet"},{"key":"476_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/mds.23455","volume":"26","author":"GM Halliday","year":"2011","unstructured":"Halliday, G. M. & Stevens, C. H. Glia: initiators and progressors of pathology in Parkinson\u2019s disease. Mov. Disord. 26, 6\u201317 (2011).","journal-title":"Mov. Disord."},{"key":"476_CR3","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/mds.26563","volume":"31","author":"CH Williams-Gray","year":"2016","unstructured":"Williams-Gray, C. H. et al. Serum immune markers and disease progression in an incident Parkinson\u2019s disease cohort (ICICLE-PD). Mov. Disord. 31, 995\u20131003 (2016).","journal-title":"Mov. Disord."},{"key":"476_CR4","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/jamaneurol.2017.0469","volume":"74","author":"A Witoelar","year":"2017","unstructured":"Witoelar, A. et al. Genome-wide pleiotropy between Parkinson disease and autoimmune diseases. JAMA Neurol. 74, 780\u2013792 (2017).","journal-title":"JAMA Neurol."},{"key":"476_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.692","volume":"12","author":"L Caldi Gomes","year":"2022","unstructured":"Caldi Gomes, L. et al. Multi-omic landscaping of human midbrains identifies disease-relevant molecular targets and pathways in advanced-stage Parkinson\u2019s disease. Clin. Transl. Med. 12, e692 (2022).","journal-title":"Clin. Transl. Med."},{"key":"476_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/mds.28264","volume":"36","author":"AS Harms","year":"2021","unstructured":"Harms, A. S. et al. Inflammation in experimental models of alpha-synucleinopathies. Mov. Disord. 36, 37\u201349 (2021).","journal-title":"Mov. Disord."},{"key":"476_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00401-021-02268-5","volume":"141","author":"AS Harms","year":"2021","unstructured":"Harms, A. S., Ferreira, S. A. & Romero-Ramos, M. Periphery and brain, innate and adaptive immunity in Parkinson\u2019s disease. Acta Neuropathol. 141, 527\u2013545 (2021).","journal-title":"Acta Neuropathol."},{"key":"476_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/0304-3940(94)90746-3","volume":"165","author":"M Mogi","year":"1994","unstructured":"Mogi, M. et al. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165, 208\u2013210 (1994).","journal-title":"Neurosci. Lett."},{"key":"476_CR9","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s10571-020-01027-6","volume":"42","author":"FM de Araujo","year":"2021","unstructured":"de Araujo, F. M. et al. Role of microgliosis and NLRP3 inflammasome in Parkinson\u2019s disease pathogenesis and therapy. Cell Mol. Neurobiol. 42, 1283\u20131300 (2021).","journal-title":"Cell Mol. Neurobiol."},{"key":"476_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson, K. V., Deng, M. & Ting, J. P. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477\u2013489 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"476_CR11","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature22815","volume":"546","author":"D Sulzer","year":"2017","unstructured":"Sulzer, D. et al. T cells from patients with Parkinson\u2019s disease recognize alpha-synuclein peptides. Nature 546, 656\u2013661 (2017).","journal-title":"Nature"},{"key":"476_CR12","doi-asserted-by":"publisher","first-page":"946","DOI":"10.3389\/fneur.2018.00946","volume":"9","author":"AJ White","year":"2018","unstructured":"White, A. J. et al. The peripheral inflammatory response to alpha-synuclein and endotoxin in Parkinson\u2019s disease. Front. Neurol. 9, 946 (2018).","journal-title":"Front. Neurol."},{"key":"476_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/ene.13223","volume":"24","author":"K Brockmann","year":"2017","unstructured":"Brockmann, K. et al. Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson\u2019s disease. Eur. J. Neurol. 24, 427\u2013e426 (2017).","journal-title":"Eur. J. Neurol."},{"key":"476_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s40478-020-01083-5","volume":"8","author":"A Kouli","year":"2020","unstructured":"Kouli, A., Camacho, M., Allinson, K. & Williams-Gray, C. H. Neuroinflammation and protein pathology in Parkinson\u2019s disease dementia. Acta Neuropathol. Commun. 8, 211 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"476_CR15","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/mds.28015","volume":"35","author":"RS Wijeyekoon","year":"2020","unstructured":"Wijeyekoon, R. S. et al. Cerebrospinal fluid cytokines and neurodegeneration-associated proteins in Parkinson\u2019s disease. Mov. Disord. 35, 1062\u20131066 (2020).","journal-title":"Mov. Disord."},{"key":"476_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.bbi.2020.01.018","volume":"87","author":"RS Wijeyekoon","year":"2020","unstructured":"Wijeyekoon, R. S. et al. Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson\u2019s disease. Brain Behav. Immun. 87, 473\u2013488 (2020).","journal-title":"Brain Behav. Immun."},{"key":"476_CR17","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.3233\/JPD-223277","volume":"12","author":"M Zimmermann","year":"2022","unstructured":"Zimmermann, M. & Brockmann, K. Blood and cerebrospinal fluid biomarkers of inflammation in Parkinson\u2019s disease. J. Parkinson\u2019s Dis. 12, S183\u2013S200 (2022).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"476_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15626-w","volume":"11","author":"CS Lindestam Arlehamn","year":"2020","unstructured":"Lindestam Arlehamn, C. S. et al. alpha-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson\u2019s disease. Nat. Commun. 11, 1875 (2020).","journal-title":"Nat. Commun."},{"key":"476_CR19","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/mds.28122","volume":"35","author":"A Kouli","year":"2020","unstructured":"Kouli, A. & Williams-Gray, C. H. Timing is everything: The T-cell response to alpha-synuclein is maximal in early Parkinson\u2019s. Mov. Disord. 35, 1137 (2020).","journal-title":"Mov. Disord."},{"key":"476_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-017-0935-1","volume":"14","author":"LN Eidson","year":"2017","unstructured":"Eidson, L. N. et al. Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson\u2019s disease. J. Neuroinflammation 14, 164 (2017).","journal-title":"J. Neuroinflammation"},{"key":"476_CR21","doi-asserted-by":"publisher","first-page":"834580","DOI":"10.3389\/fneur.2022.834580","volume":"13","author":"S Lerche","year":"2022","unstructured":"Lerche, S. et al. CSF and serum levels of inflammatory markers in PD: sparse correlation, sex differences and association with neurodegenerative biomarkers. Front. Neurol. 13, 834580 (2022).","journal-title":"Front. Neurol."},{"key":"476_CR22","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1212\/NXG.0000000000000523","volume":"6","author":"L Straniero","year":"2020","unstructured":"Straniero, L. et al. The SPID-GBA study: sex distribution, penetrance, incidence, and dementia in GBA-PD. Neurol. Genet. 6, e523 (2020).","journal-title":"Neurol. Genet."},{"key":"476_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","volume":"13","author":"D Aarsland","year":"2017","unstructured":"Aarsland, D. et al. Cognitive decline in Parkinson disease. Nat. Rev. Neurol. 13, 217\u2013231 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"476_CR24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10517-020-04723-x","volume":"168","author":"IV Miliukhina","year":"2020","unstructured":"Miliukhina, I. V. et al. Plasma cytokines profile in patients with Parkinson\u2019s disease associated with mutations in GBA gene. Bull. Exp. Biol. Med. 168, 423\u2013426 (2020).","journal-title":"Bull. Exp. Biol. Med."},{"key":"476_CR25","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.3233\/JPD-212624","volume":"11","author":"A Thaler","year":"2021","unstructured":"Thaler, A. et al. Mutations in GBA and LRRK2 are not associated with increased inflammatory markers. J. Parkinson\u2019s Dis. 11, 1285\u20131296 (2021).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"476_CR26","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/mds.28525","volume":"36","author":"J Galper","year":"2021","unstructured":"Galper, J. et al. Cytokines and Gaucher biomarkers in glucocerebrosidase carriers with and without Parkinson disease. Mov. Disord. 36, 1451\u20131455 (2021).","journal-title":"Mov. Disord."},{"key":"476_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3389\/fnins.2019.00255","volume":"13","author":"TH Lian","year":"2019","unstructured":"Lian, T. H. et al. Tremor-dominant in Parkinson disease: the relevance to iron metabolism and inflammation. Front. Neurosci. 13, 255 (2019).","journal-title":"Front. Neurosci."},{"key":"476_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31517-z","volume":"8","author":"S Hall","year":"2018","unstructured":"Hall, S. et al. Cerebrospinal fluid concentrations of inflammatory markers in Parkinson\u2019s disease and atypical parkinsonian disorders. Sci. Rep. 8, 13276 (2018).","journal-title":"Sci. Rep."},{"key":"476_CR29","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s12017-018-8499-5","volume":"20","author":"H Sanjari Moghaddam","year":"2018","unstructured":"Sanjari Moghaddam, H. et al. Cerebrospinal fluid C-reactive protein in Parkinson\u2019s disease: associations with motor and non-motor symptoms. Neuromolecular Med. 20, 376\u2013385 (2018).","journal-title":"Neuromolecular Med."},{"key":"476_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41531-020-00124-z","volume":"6","author":"A Santaella","year":"2020","unstructured":"Santaella, A. et al. Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson\u2019s disease. NPJ Parkinsons Dis. 6, 21 (2020).","journal-title":"NPJ Parkinsons Dis."},{"key":"476_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.bbi.2013.07.007","volume":"33","author":"D Lindqvist","year":"2013","unstructured":"Lindqvist, D. et al. Cerebrospinal fluid inflammatory markers in Parkinson\u2019s disease\u2013associations with depression, fatigue, and cognitive impairment. Brain Behav. Immun. 33, 183\u2013189 (2013).","journal-title":"Brain Behav. Immun."},{"key":"476_CR32","doi-asserted-by":"publisher","first-page":"e0135458","DOI":"10.1371\/journal.pone.0135458","volume":"10","author":"M Wennstrom","year":"2015","unstructured":"Wennstrom, M. et al. The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer\u2019s but not Parkinson\u2019s disease or dementia with Lewy bodies. PLoS ONE 10, e0135458 (2015).","journal-title":"PLoS ONE"},{"key":"476_CR33","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.nbd.2011.05.017","volume":"43","author":"MT Armentero","year":"2011","unstructured":"Armentero, M. T. et al. Adhesion molecules as potential targets for neuroprotection in a rodent model of Parkinson\u2019s disease. Neurobiol. Dis. 43, 663\u2013668 (2011).","journal-title":"Neurobiol. Dis."},{"key":"476_CR34","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.expneurol.2005.10.034","volume":"197","author":"J Miklossy","year":"2006","unstructured":"Miklossy, J. et al. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp. Neurol. 197, 275\u2013283 (2006).","journal-title":"Exp. Neurol."},{"key":"476_CR35","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.biocel.2003.10.019","volume":"36","author":"M Maurer","year":"2004","unstructured":"Maurer, M. & von Stebut, E. Macrophage inflammatory protein-1. Int. J. Biochem. Cell Biol. 36, 1882\u20131886 (2004).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"476_CR36","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1172\/JCI200420001","volume":"113","author":"L Sun","year":"2004","unstructured":"Sun, L., Lee, J. & Fine, H. A. Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury. J. Clin. Investig. 113, 1364\u20131374 (2004).","journal-title":"J. Clin. Investig."},{"key":"476_CR37","doi-asserted-by":"publisher","unstructured":"Jewell, S., Herath, A. M. & Gordon, R. Inflammasome activation in Parkinson\u2019s disease. J. Parkinsons Dis. https:\/\/doi.org\/10.3233\/JPD-223338 (2022).","DOI":"10.3233\/JPD-223338"},{"key":"476_CR38","doi-asserted-by":"publisher","first-page":"5928","DOI":"10.1007\/s12035-016-0108-8","volume":"54","author":"H Liu","year":"2017","unstructured":"Liu, H. et al. Pterostilbene attenuates early brain injury following subarachnoid hemorrhage via inhibition of the NLRP3 inflammasome and Nox2-related oxidative stress. Mol. Neurobiol. 54, 5928\u20135940 (2017).","journal-title":"Mol. Neurobiol."},{"key":"476_CR39","doi-asserted-by":"publisher","first-page":"7053","DOI":"10.1002\/jcb.27023","volume":"119","author":"Q Li","year":"2018","unstructured":"Li, Q. et al. Pterostilbene inhibits amyloid-beta-induced neuroinflammation in a microglia cell line by inactivating the NLRP3\/caspase-1 inflammasome pathway. J. Cell Biochem. 119, 7053\u20137062 (2018).","journal-title":"J. Cell Biochem."},{"key":"476_CR40","doi-asserted-by":"publisher","first-page":"862187","DOI":"10.3389\/fphys.2022.862187","volume":"13","author":"L Zhang","year":"2022","unstructured":"Zhang, L., Jian, X., Yu, J. & Yu, J. Pterostilbene interferes with lipopolysaccharide-induced myocardial injury through oxidative stress and inflammasome pathways. Front. Physiol. 13, 862187 (2022).","journal-title":"Front. Physiol."},{"key":"476_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/srep34132","volume":"6","author":"S Ferenczi","year":"2016","unstructured":"Ferenczi, S., Szegi, K., Winkler, Z., Barna, T. & Kovacs, K. J. Oligomannan prebiotic attenuates immunological, clinical and behavioral symptoms in mouse model of inflammatory bowel disease. Sci. Rep. 6, 34132 (2016).","journal-title":"Sci. Rep."},{"key":"476_CR42","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.3390\/ijms23126756","volume":"23","author":"I Hecking","year":"2022","unstructured":"Hecking, I. et al. Neuroprotective effects of VEGF in the enteric nervous system. Int. J. Mol. Sci. 23, 6756 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"476_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-4-49","volume":"4","author":"T Falk","year":"2009","unstructured":"Falk, T., Zhang, S. & Sherman, S. J. Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson\u2019s disease. Mol. Neurodegeneration 4, 49 (2009).","journal-title":"Mol. Neurodegeneration"},{"key":"476_CR44","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/ng1395","volume":"36","author":"L Cao","year":"2004","unstructured":"Cao, L. et al. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat. Genet. 36, 827\u2013835 (2004).","journal-title":"Nat. Genet."},{"key":"476_CR45","doi-asserted-by":"publisher","first-page":"5081","DOI":"10.1073\/pnas.1007640108","volume":"108","author":"T Licht","year":"2011","unstructured":"Licht, T. et al. Reversible modulations of neuronal plasticity by VEGF. Proc. Natl Acad. Sci. USA 108, 5081\u20135086 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"476_CR46","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1038\/mp.2015.195","volume":"21","author":"P De Rossi","year":"2016","unstructured":"De Rossi, P. et al. A critical role for VEGF and VEGFR2 in NMDA receptor synaptic function and fear-related behavior. Mol. Psychiatry 21, 1768\u20131780 (2016).","journal-title":"Mol. Psychiatry"},{"key":"476_CR47","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1001\/jamaneurol.2014.4761","volume":"72","author":"TJ Hohman","year":"2015","unstructured":"Hohman, T. J., Bell, S. P. & Jefferson, A. L., Alzheimer\u2019s Disease Neuroimaging, I. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease. JAMA Neurol. 72, 520\u2013529 (2015).","journal-title":"JAMA Neurol."},{"key":"476_CR48","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/mds.10459","volume":"18","author":"I Litvan","year":"2003","unstructured":"Litvan, I. et al. Movement disorders society scientific issues committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov. Disord. 18, 467\u2013486 (2003).","journal-title":"Mov. Disord."},{"key":"476_CR49","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89, 88\u2013100 (2017).","journal-title":"Neurology"},{"key":"476_CR50","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Movement disorder society-sponsored revision of the unified Parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129\u20132170 (2008).","journal-title":"Mov. Disord."},{"key":"476_CR51","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz, C. G. et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov. Disord. 19, 1020\u20131028 (2004).","journal-title":"Mov. Disord."},{"key":"476_CR52","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1212\/WNL.0b013e3181c34b47","volume":"73","author":"S Hoops","year":"2009","unstructured":"Hoops, S. et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73, 1738\u20131745 (2009).","journal-title":"Neurology"},{"key":"476_CR53","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein, M. F., Folstein, S. E. & McHugh, P. R. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189\u2013198 (1975).","journal-title":"J. Psychiatr. Res."},{"key":"476_CR54","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/jgs.14779","volume":"65","author":"D Bergeron","year":"2017","unstructured":"Bergeron, D. et al. Multicenter validation of an MMSE-MoCA conversion table. J. Am. Geriatr. Soc. 65, 1067\u20131072 (2017).","journal-title":"J. Am. Geriatr. Soc."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00476-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00476-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00476-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T07:05:58Z","timestamp":1678518358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00476-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["476"],"URL":"https:\/\/doi.org\/10.1038\/s41531-023-00476-2","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"4 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Katharina Waniek and Ingolf Lachmann declare no competing non-financial interests, but the following competing financial interests: Katharina Waniek and Ingolf Lachmann are employed by Roboscreen GmbH which manufactures the ELISA kit for measurements of total human \u03b1-synuclein used in the present study. The remaining authors declare that the research was conducted in the absence of any commercial or financial and non-financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}